In this study, we explored if PARP inhibition alone or in combination with chemo- or radiotherapy could be a potential therapeutic strategy for chondrosarcoma and whether sensitivity towards these therapies depends on the IDH mutation status. The gene discussed is IDH2; the disease is chondrosarcoma.